Yutiq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871241 EYEPOINT PHARMS Injectable sustained release delivery devices
Aug, 2027

(3 years from now)

US7998108 EYEPOINT PHARMS Injector apparatus and method of use
Jan, 2028

(4 years from now)

Yutiq is owned by Eyepoint Pharms.

Yutiq contains Fluocinolone Acetonide.

Yutiq has a total of 2 drug patents out of which 0 drug patents have expired.

Yutiq was authorised for market use on 12 October, 2018.

Yutiq is available in implant;intravitreal dosage forms.

Yutiq can be used as a method of injecting an implant.

The generics of Yutiq are possible to be released after 12 January, 2028.

Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 12 October, 2018

Treatment: A method of injecting an implant


More Information on Dosage

YUTIQ family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic